Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267864 | 0.90 | ESR1 (0.33) | NPC1MEN1KMT2ALMNAPOLB | |
| SCHEMBL2116795 | 0.84 | NPC1 (0.42) | NPC1BCHESIGMAR1CARM1PRMT6 | |
| SCHEMBL26493887 | 0.83 | NPC1 (0.41) | NPC1MEN1KMT2ABCHELMNA | |
| SCHEMBL2118658 | 0.80 | NPC1 (0.39) | NPC1BCHEHRH1 | |
| SCHEMBL2114252 | 0.80 | HRH1 (0.40) | NPC1MEN1KMT2ABCHELMNA | |
| SCHEMBL2886464 | 0.79 | NPC1 (0.35) | NPC1HRH1 | |
| SCHEMBL26493937 | 0.78 | NPC1 (0.40) | NPC1KMT2ABCHE | |
| SCHEMBL22852605 | 0.76 | HRH3 (0.39) | NPC1SIGMAR1CARM1PRMT6 | |
| SCHEMBL2116387 | 0.76 | HRH3 (0.37) | MEN1KMT2ALMNAPOLBHRH1 | |
| SCHEMBL2117160 | 0.75 | BCHE (0.36) | NPC1MEN1KMT2ABCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | NPC1 3767/4885MEN1 1263/4885KMT2A 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.